TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Ligand Pharmaceuticals
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Ligand Pharmaceuticals announced 2026 full year revenue guidance of $245-$285 million, representing a 15% core revenue growth, with strong expectations for royalty revenue from key pharmaceutical products.

Insights
LGND   positive

Company projected strong revenue growth, increased royalty revenue, and robust investment strategy for 2026